Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Apr 15, 2025; 17(4): 103131
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103131
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103131
Table 5 Comparison of adverse events between the two groups, n (%)
| Variables | Total (n = 115) | Control group (n = 56) | RH-endostatin group (n = 59) | χ2 | P value |
| Hematological toxicity | 55 (47.8) | 30 (53.5) | 25 (42.3) | 1.444 | 0.230 |
| Leucopenia | 35 (30.4) | 19 (33.9) | 16 (27.1) | ||
| Anemia | 8 (7.0) | 5 (8.9) | 3 (5.1) | ||
| Thrombocytopenia | 12 (10.4) | 6 (10.7) | 6 (10.2) | ||
| Non-hematological toxicity | 58 (50.4) | 32 (57.1) | 26 (44.1) | 2.507 | 0.113 |
| Nausea, vomiting | 33 (28.7) | 18 (32.1) | 15 (25.4) | ||
| Constipation | 7 (6.1) | 4 (7.1) | 3 (5.1) | ||
| Tiredness | 12 (10.4) | 7 (12.5) | 5 (8.5) | ||
| Liver dysfunction | 6 (5.2) | 3 (5.4) | 3 (5.1) | ||
| Anti-vascular specific toxicity | 14 (12.1) | 9 (15.2) | 5 (8.5) | 1.566 | 0.2611 |
| Secondary hypertension | 2 (1.7) | 2 (3.6) | 0 (0) | ||
| Secondary proteinuria | 4 (3.5) | 3 (5.4) | 1 (1.7) | ||
| Hemorrhage | 3 (2.6) | 2 (3.6) | 1 (1.7) | ||
| Chemical peritonitis | 5 (4.3) | 2 (3.6) | 3 (5.1) |
- Citation: Liu Y, Liu HG, Zhao C. Intraperitoneal perfusion of endostatin improves the effectiveness and prolongs the prognosis of patients with gastric cancer. World J Gastrointest Oncol 2025; 17(4): 103131
- URL: https://www.wjgnet.com/1948-5204/full/v17/i4/103131.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i4.103131